UTMB’s Thomas Geisbert and his collaborators at Profectus Biosciences have developed two new Ebola vaccines that protect monkeys against the strain of the virus responsible for the current deadly outbreak. Only one dose was needed, and there were no apparent side effects. Safety trials in healthy volunteers will likely begin early this summer. These findings were published by Nature on April 8.
Coverage of Geisbert’s new vaccine has received extensive coverage across the globe including the following media outlets, among many others:
NBC News, Time Magazine, Los Angeles Times, Texas Medical Center News, Galveston Daily News, Houston Chronicle, Dallas Morning News, CNBC, Bloomberg Business, U.S. News and World Report, Houston Business Journal, Dallas Business Journal, San Antonio Business Journal, Baltimore Business Journal, The Business Journals, Houston Press, Sierra Leone Times, Economic Times, United Press International, Infection Control Today, Baltimore Sun, Medical Xpress, Military Technologies, Galveston.com and Co., Health Canal, Drug Discovery & Development, Science Daily, Global Biodefense, BioSpace, ClinicaSpace, Drug Discovery & Development, Delhi Daily News, Health.com, Drugs.com, Doctor’s Lounge, MedicineNet, HealthFinder.gov, Ticker Technologies, The Health Cast, Health on the New Foundation, Tech Times, India Online, The Tribune, National Monitor, New Hampshire Voice, The Standard Daily, Geek Infinite, Pharmi Web, Diabetes Insider, News Medical, Philadelphia Inquirer, Yahoo! India, Yahoo! Singapore, The New Indian Express, The Silver Ink, Bright Surf, Business Standard, Zee News, Machines Like Us, BioMedReports, Democratic Underground, Bright Surf, World Pharma News, Medical News Today, National Monitor, News Hub, Microfinance Monitor, American Register, Outlook India, The Medical News, FirstWord Pharma, Vancouver Desi, Bio-Medicine, Kaiser Family Foundation, and The State Journal.